All In Biotech

Free tool

FAERS Monitor: Idhifa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209606 or its brand name (Idhifa, Enasidenib Mesylate). Reports on generic versions are filed under their own applications.

Reports

3,369

Serious

2,076

62% of reports

Hospitalization

864

Death reported

839

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death682
  • off label use246
  • fatigue224
  • nausea197
  • hospitalisation186
  • diarrhoea142
  • platelet count decreased133
  • decreased appetite121
  • acute myeloid leukaemia119
  • drug ineffective102
  • asthenia92
  • full blood count decreased81
  • white blood cell count decreased76
  • pyrexia74
  • pneumonia68

Reports by year received

View as table
YearReports
201790
2018400
2019424
2020548
2021395
2022317
2023372
2024377
2025276
2026170

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute myeloid leukaemiaSignal11948.040.25,395
full blood count decreasedSignal8125.220.31,852
platelet count decreasedSignal1337.86.6785
hospitalisationSignal1867.66.61,060
deathSignal6824.94.62,232
white blood cell count decreasedSignal764.43.5196
decreased appetiteSignal1213.32.7189
fatigue2241.81.681
off label use2461.81.682
nausea1971.61.440
asthenia921.51.217
diarrhoea1421.41.214
pyrexia741.31.16
pneumonia681.31.05
drug ineffective1020.50.460

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.